Arena Pharma Could Be Developing Several Best-In-Class Agents By: Benzinga via Benzinga May 19, 2017 at 14:59 PM EDT Leerink initiated coverage of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) with an Outperform rating and a $5 price target. New ... Read More >>